The novel nanoparticle delivered Mp6 peptide was able to inhibit thrombosis and reduce inflammation without increasing the risk of bleeding in mice after heart attacks.
List view / Grid view
Filter the results
Expert view: GenScript’s unique four-tier platform for successful synthesis of challenging neoantigen peptides for precision medicine
Despite hundreds of off-the-shelf treatments, cancer remains the second leading cause of death globally.
Scientists have developed a new antimicrobial peptide therapy named D8 with high efficacy and low toxicity in mice which could be used to fight lung infections.
The University of Georgia and CEL-SCI Corporation have partnered to develop an immunotherapy to combat the COVID-19 coronavirus using the Ligand Antigen Epitope Presentation System (LEAPS) technology.
Combining the chlorotoxin peptide with conventional CAR structures, researchers have created a new CAR T cell therapy that has successfully combatted glioblastomas in mice.
Researchers have used a peptide called D6PV to lower triglycerides in mouse models, which could be used as a therapy for high triglyceride-induced acute pancreatitis in humans.
A key receptor has been examined for the first time at high resolution which could lead to better treatments for conditions such as type 2 diabetes.
A new technique has been developed which has the potential to harness bacteria to produce billions of different drug candidates to treat diseases like cancer.
A study has identified a protein complex elevated in PTSD patients and developed a peptide to disrupt it, preventing the recall of fear memories in early tests and paving the way for new therapies.
Unlike synthetic compound libraries, natural product hits must be identified and characterised, as the molecule is often unknown. Venom peptides are often inherently stable due to cysteine knots whereas other peptides may not be. Steve and Carol Trim discuss the challenges of the hit-to-lead journey with these non-standard hits.
A group of scientists from India have used 3D imaging of the Nipah virus to discover potential inhibitors for the disease.
This issue includes a discussion on the future of high-throughput screening through collaboration, an analysis of mass spectrometry as a structural biology tool and an exploration of the challenges of hit-to-lead when researching tropical diseases. Also in the issue are articles on immuno-oncology and assays.
Researchers have developed a novel peptide with a prolonged half-life that has demonstrated success in rhesus monkeys and mice for inhibiting HIV infections.